Considering the fragile ocular surface of patients with glaucoma and the side effects of β-blocker eye drops on the ocular surface, non-selective β-blocker eye drops may not be the first choice for glaucoma treatment, whereas our results suggested that a selective β1AR antagonist, such as betaxolol or any other type of anti-glaucoma agent should be considered. This evidence concerns the gene ADRB1 and glaucoma.